What BPC-157 is and how it works
BPC-157, short for Body Protection Compound 157, is a pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described as a partial sequence of a larger protein, BPC, which the group of Predrag Sikirić at the University of Zagreb reported isolating from human gastric juice in the early 1990s. The peptide used in research is made synthetically; the parent protein has not been characterised in detail elsewhere in the literature.
Two features shaped how BPC-157 has been studied. The Zagreb group reports that it survives gastric juice, so many of its rat experiments gave the peptide in drinking water or directly into the stomach as well as by injection. It is also reported to act across an unusually wide range of tissues: gut, tendon, ligament, muscle, bone, blood vessels, liver and nervous system all appear in its literature. That breadth is remarkable for one small peptide, and it is one reason researchers elsewhere treat the literature cautiously.
No receptor for BPC-157 has been identified. The proposed mechanisms come from animal and cell work: increased expression of vascular endothelial growth factor and activation of its receptor VEGFR2, which drive the growth of new blood vessels; effects on the nitric oxide system, which governs blood flow and vessel repair; and, in cultured tendon fibroblasts, faster cell migration linked to the FAK–paxillin pathway and increased expression of the growth hormone receptor. These are plausible links rather than a mapped path from a receptor to an effect.
What the research on BPC-157 shows
The literature is large in volume and narrow in origin. Most of it consists of rat experiments from the Zagreb group: cut tendons and ligaments, crushed muscle, bowel anastomoses and fistulas, stomach ulcers, drug-induced organ damage and many other models. They consistently report better healing with BPC-157 than with saline. A smaller set of cell and animal studies from other laboratories, notably tendon-fibroblast work from Taiwan, points the same way, but it is not a broad replication.
Several features limit how far this evidence reaches. Many experiments are small, and the reporting of randomisation and blinding varies. Effects are often reported both at 10 µg/kg and at 10 ng/kg, a thousand-fold lower dose, which is hard to reconcile with an ordinary dose–response relationship. And positive results from one group, however many, weigh less than the same results from several unconnected laboratories. Evidence level: almost entirely rodent.
Human evidence is thin. The Zagreb group has referred to early clinical testing in inflammatory bowel disease, but no full peer-reviewed report of a controlled trial has appeared. Beyond that there are a few small uncontrolled reports, such as a retrospective case series on knee pain. No randomised controlled trial of BPC-157 for any condition has been published. The rat data show a consistent signal from one main source; they do not establish that BPC-157 heals human tissue, at what dose, or with what risks.
BPC-157 doses used in published research
| Species | Dose | Route | Notes |
|---|---|---|---|
| Rat | 10 µg/kg | Intraperitoneal injection | The dose used most often in Zagreb studies |
| Rat | 10 ng/kg | Intraperitoneal injection | Frequently tested alongside the µg/kg dose |
| Rat | 10 µg/kg or 10 ng/kg | In drinking water | Tests the oral route; rests on the reported gastric stability |
| Human | No validated dose | – | No controlled trials published |
Those doses are small by the standards of peptide pharmacology, and the nanogram dose is reported to work in many of the same models as the microgram dose. Converting either into a human dose, by body weight or any scaling formula, would be guesswork: the rat data do not establish a dose–response curve, and there are no controlled human studies to anchor them. The table records study designs; it is not a dosing guide.
BPC-157 safety and side effects
The rat studies report few adverse effects, but they were built to test healing, not safety. What has not been studied matters more here than what has been reported.
- No controlled human safety data. Without randomised trials, the type and frequency of adverse effects in people are simply unknown.
- Angiogenesis and tumours. BPC-157 appears to promote new blood-vessel growth, partly through VEGF signalling, and tumours depend on the same process. The theoretical concern that it could support an existing tumour has not been demonstrated, but it has not been properly tested either.
- Long-term exposure. Little is known about repeated exposure over months in any species.
- Material quality. There is no pharmaceutical-grade BPC-157, so identity and purity rest on the supplier and the certificate that comes with the vial.
Regulatory status of BPC-157 in Europe
BPC-157 is not authorised as a medicine in the European Union, and no medicines regulator elsewhere has approved it. Research material carries no marketing authorisation and is not intended for human use; rules on possession and import differ between member states.
Since 2022, BPC-157 has been named on the World Anti-Doping Agency Prohibited List under S0, the category for pharmacological substances with no current approval by any government health authority for human therapeutic use. Like everything in S0, it is prohibited at all times, in and out of competition.
Sourcing BPC-157 and checking quality
King Peptides sells BPC-157 10 mg as a single compound. It is also part of two blends: the Wolverine Stack - BPC-157 + TB-500 5/5 mg, which pairs it with TB-500, a thymosin beta-4 product, and the KLOW-80 Blend - GHK-Cu + BPC-157 + TB-500 + KPV, which adds the copper tripeptide GHK-Cu and the tripeptide KPV. Work that has to attribute an effect to BPC-157 needs the single compound; the blends, and the limits they place on a study design, are covered in our guide to peptide combinations in research.
On the certificate, check that the lot number matches the vial, that HPLC purity is at least 99% and that the mass is close to 1419.5 Da. In a blend, every component should be identified by its own mass. King Peptides supplies a lot-specific certificate with HPLC and mass spectrometry and dispatches from the Netherlands in neutral packaging with tracking; by the shop's own estimate delivery takes 1–2 business days in the Netherlands and 3–5 business days elsewhere in the EU, with no customs inside the EU, while shipments to non-EU countries such as the UK, Switzerland or Norway can meet import rules and duties. Our guides explain how to read a certificate of analysis and how to store and reconstitute peptides.
BPC-157: frequently asked questions
Is there human evidence for BPC-157? Only a few small uncontrolled reports. No randomised controlled trial has been published, so nothing is established about its effects or its safety in people.
Why do so many BPC-157 studies come from Zagreb? The peptide was identified and developed there, and the same group has published on it for more than 30 years. Replication by unconnected laboratories remains limited, which is the single biggest weakness in the evidence.
Why do rat studies give BPC-157 in drinking water? Because the Zagreb group reports that it survives gastric juice. The design tests the oral route in rats; there are no controlled data on oral absorption in humans.
Is BPC-157 banned in sport? Yes. It has been named under S0 of the WADA Prohibited List since 2022 and is prohibited at all times.
Research use only. BPC-157 is described here for laboratory and scientific research. Research material carries no marketing authorisation, whatever the status of the molecule as a medicine elsewhere, and it is not intended for human or veterinary use. Nothing on this page is medical advice, and the dosing information above summarises published study designs. Always comply with the laws that apply in your country.